Fidelity Investments’s NeuroOne Medical Technologies NMTC Stock Holding History

Fidelity Investments’s Portfolio NMTC Stock Details NMTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7	Closed	–	–	5309
2022 Q1	$0	Hold	7	–	–	﹤0.01%	5313
2021 Q4	$0	Buy	+7	New	+$113	﹤0.01%	4744

Other funds holding NMTC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DWM

Drive Wealth Management Lehi, Utah $561M AUM 33.14% 1-Year Est. Return

KCIA

Kingsbury Capital Investment Advisors Wilmette, Illinois $65.6M AUM

Intersect Capital San Ramon, California $331M AUM 6.79% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity Investments's NMTC Position: Q2 2022 in Review

Fidelity Investments sold out of NeuroOne Medical Technologies (NMTC) in Q2 2022, closing a stake of 7 shares.

Fidelity Investments first reported a position in NMTC in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 10 funds tracked by Wall St. Rank hold NMTC as of Q2 2022.

Fidelity Investments reported no remaining NeuroOne Medical Technologies position as of Q2 2022 after selling out during the quarter.
Fidelity Investments sold 7 NeuroOne Medical Technologies shares in Q2 2022.
Fidelity Investments first reported a position in NeuroOne Medical Technologies in Q4 2021 and held it in 2 quarters.
Fidelity Investments's NeuroOne Medical Technologies position peaked at $0 in Q1 2022.
10 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2022.

Based on Fidelity Investments's 13F filing for Q2 2022, filed 12 Aug 2022.